Cyxone

Cyxone is a Malmö-based clinical-stage biotech company developing rabeximod, a novel anti-inflammatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. The compound targets macrophage-driven inflammation through a unique mechanism of action. Listed on Nasdaq First North, Cyxone is advancing rabeximod through clinical development.